Author:
Nnane I. P.,Tsai M-C.,Lin G.,Damani L. A.,Mitterhauser M.,Zolle I.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference10 articles.
1. Sarkar S.D., Cohen E.L., Beierwaltes W.H., Ice R.D., Cooper R., Gold E.N. (1977): A new and superior adrenal imaging agent, I-131-6β-iodomethyl-19-norcholesterol (NP-59). Evaluation in humans. J. Clin. Endocrinol. Metab., 45: 163–172.
2. Damani L.A., Mitterhauser M., Zolle I., Lin G., Oehler E., Ho Y. P. (1995): Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology. Nucl. Med. Biol., 22: 1067–1074.
3. Hilderbrandt A.G. (1971): The binding of metyrapone to cytochrome P-450 and its inhibitory action on liver microsomal mixed-function oxidase reactions. Biochem. J., 125: 6P.
4. Napoli J.L., Counsell R.E. (1977): New inhibitors of steroid 11β-hydroxylase. Structure-activity relationship studies of metyrapone-like compounds. J. Med. Chem., 20: 762–766.
5. Zolle I., Yu J., Robien W., Woloszczuk W., Hîfer R. (1991): Biochemical evaluation of metyrapone derivatives — inhibition kinetics and affinity studies. J. Labelled Compd Radiopharm., 30: 420–422.